Skip to main content
. 2015 Oct 19;7(11):1480–1502. doi: 10.15252/emmm.201505246

Figure 1. Cumulative survival according to MICA-129 genotype.

Figure 1

  1. Kaplan–Meier survival curves stratified by the patient MICA-129 genotype for all patients (n = 446). The survival curve is displayed for the first 66 months; 7.6% of the patients were followed longer. Effects on overall survival were determined by Cox regression with covariate adjustment as indicated in Table2. The HR indicates the risk per MICA-129Met allele carried by the patients (additive risk model). The numbers of patients carrying the three genotypes and the number of events (in brackets) are indicated.
  2. Kaplan–Meier survival curves for patients receiving a graft matched for the MICA-129 genotype (n = 404).
  3. Kaplan–Meier survival curves for patients who experienced aGVDH (any grade, n = 244).
  4. Kaplan–Meier survival curves for patients not experiencing aGVHD (n = 189). The HR indicates the risk of patients carrying two MICA-129Met alleles (recessive risk model).
  5. Kaplan–Meier survival curves for patients who did not receive a T-cell-depleting treatment with ATG (n = 193).
  6. Kaplan–Meier survival curves for patients treated with ATG (n = 250).
  7. Kaplan–Meier survival curves for patients with the MICA-129Val/Val genotype (n = 229) stratified by treatment with ATG.
  8. Kaplan–Meier survival curves for patients carrying one or two MICA-129Met alleles (n = 214) stratified by treatment with ATG.